The patent allowance is a modest positive catalyst that reinforces GelrinC's competitive moat in Japan. Traders should watch for updates on European commercial launch timing and U.S. trial enrollment completion (currently >50%) as nearer-term value drivers.
Price Chart
Executive Summary
Regentis received a Japanese patent allowance for its proprietary organic solvent-free manufacturing process used in GelrinC, strengthening its IP portfolio in the world's second-largest cartilage repair market. The patent covers a 5x yield improvement in manufacturing and supports the company's European commercialization and U.S. pivotal trial progress.
Key Facts
- Japan Patent Office issued Notice of Allowance for patent covering organic solvent-free manufacturing process for GelrinC
- Patent provides IP protection in Japan, a cartilage repair market estimated at nearly $289 million by 2030
- Technology offers 5x increase in manufacturing yield, improved environmental profile, and scalability
- GelrinC has CE Mark approval in EU; U.S. pivotal FDA trial has surpassed 50% enrollment
- Approximately 25 million people in Japan over 40 have radiographic knee osteoarthritis, with ~8 million symptomatic
Financial Impact
No immediate revenue impact; strengthens long-term IP position in a $289M addressable market by 2030
Risk Factors
- Patent allowance does not guarantee commercial success or FDA approval
- Company remains pre-revenue with $17M market cap; may require additional financing to fund operations and trials
- Competing cartilage repair technologies could limit market penetration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079444 |
| Document: ea029852301ex99-1.htm | 0001213900-26-079444 |
| Document: 0001213900-26-079444-index-headers.html | 0001213900-26-079444 |
| Document: 0001213900-26-079444-index.html | 0001213900-26-079444 |
| Document: 0001213900-26-079444.txt | 0001213900-26-079444 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $1.63 | awaiting T+20 | — | $1.29 (−20.62%) |
Sep 23, 2026 4w ago | EFFECT | $2.10 $1.49 | ▼ −29.05% | ▼ −29.74% | $1.29 (−38.57%) |
Jul 20, 2026 14w ago | 6-K | $2.00 $2.04 | ▲ +2.00% | ▼ −2.12% | $1.29 (−35.50%) |
Jul 15, 2026 14w ago | 6-K | $2.43 $1.94 | ▼ −20.16% | ▼ −22.51% | $1.29 (−46.91%) |
Jul 14, 2026 15w ago | EFFECT | $2.54 $1.84 | ▼ −27.56% | ▼ −30.05% | $1.29 (−49.21%) |
Jun 15, 2026 19w ago | 6-K | $9.40 $2.43 | ▲ +74.15% | ▲ +74.15% | $1.29 (+86.28%) |
Jun 9, 2026 20w ago | F-1/A | $2.41 $3.64 | ▲ +51.04% | ▲ +49.59% | $1.29 (−46.47%) |
Jun 8, 2026 20w ago | 6-K | $1.28 $3.58 | ▲ +179.69% | ▲ +178.85% | $1.29 (+0.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers